📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Dendreon

1.1 - Company Overview

Dendreon Logo

Dendreon

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of immunotherapy and cell therapy services, including PROVENGE (sipuleucel-T), an FDA-approved cellular immunotherapy for advanced prostate cancer; end-to-end cell therapy manufacturing; patient operations and logistics to deliver treatments within an 18-hour window across the U.S.; process and analytical development; and cGMP quality assurance and quality control.

Products and services

  • Cellular Therapy Manufacturing: Delivers end-to-end manufacturing services for cell therapy, assisting in development and production of cellular therapies, with an end-to-end operational scope
  • Patient Operations and Logistics Network: Manages production plans and executes delivery of cellular treatments across the U.S. within an 18-hour window, with nationwide operational scale
  • PROVENGE (sipuleucel-T): An FDA-approved cellular immunotherapy for advanced prostate cancer, engineered from a patient’s own immune cells.

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Dendreon

Linnaeus Therapeutics Logo

Linnaeus Therapeutics

HQ: United States Website
  • Description: Provider of development-stage cancer therapeutics, including LNS8801, an orally bioavailable, highly specific G protein-coupled estrogen receptor (GPER) agonist that depletes c-Myc protein levels, shows antitumor activities in preclinical cancer models, and is being tested in clinical trials as a monotherapy and with pembrolizumab.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Linnaeus Therapeutics company profile →
Transgene Logo

Transgene

HQ: France Website
  • Description: Provider of integrated immunotherapies to treat cancers and chronic infectious diseases, covering research, clinical batch manufacturing, and clinical trials. Portfolio includes TG4050 personalized neoantigen cancer vaccine using genetic engineering and AI; TG4001 therapeutic HPV-16 cancer vaccine; BT-001 (anti-CTLA4, GM-CSF) and TG6050 (IL-12, anti-CTLA4) oncolytic viruses.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Transgene company profile →
OncoEthix Logo

OncoEthix

HQ: Switzerland Website
  • Description: Provider of cancer drug development, advancing a portfolio of three to five promising oncology compounds through clinical development; a private Swiss company founded in 2007.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full OncoEthix company profile →
Kudos Pharmaceuticals Logo

Kudos Pharmaceuticals

HQ: United Kingdom Website
  • Description: Provider of drug discovery and development based on the science of DNA damage sensing, signaling, and repair to address medical needs in cancer treatment.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Kudos Pharmaceuticals company profile →
iOmx Therapeutics Logo

iOmx Therapeutics

HQ: Germany Website
  • Description: Provider of first-in-class cancer immunotherapies and discovery platforms targeting novel immune checkpoint modulators on tumor cells. Offerings include iOTargTM, a high-throughput genetic screening platform to identify checkpoint molecules; OMX-0407, an oral spectrum-selective SIK inhibitor in first-in-human trials; and IOMX-0675, a dual LILRB1/LILRB2 antibody to re-activate innate and adaptive immunity.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full iOmx Therapeutics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Dendreon

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Dendreon

2.2 - Growth funds investing in similar companies to Dendreon

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Dendreon

4.2 - Public trading comparable groups for Dendreon

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Dendreon

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Dendreon

What does Dendreon do?

Dendreon is a provider of immunotherapy and cell therapy services, including PROVENGE (sipuleucel-T), an FDA-approved cellular immunotherapy for advanced prostate cancer; end-to-end cell therapy manufacturing; patient operations and logistics to deliver treatments within an 18-hour window across the U.S.; process and analytical development; and cGMP quality assurance and quality control.

Who are Dendreon's competitors?

Dendreon's competitors and similar companies include Linnaeus Therapeutics, Transgene, OncoEthix, Kudos Pharmaceuticals, and iOmx Therapeutics.

Where is Dendreon headquartered?

Dendreon is headquartered in United States.

How many employees does Dendreon have?

Dendreon has 1,000 employees 🔒.

When was Dendreon founded?

Dendreon was founded in 2010 🔒.

What sector and industry vertical is Dendreon in?

Dendreon is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Dendreon

Who are the top strategic acquirers in Dendreon's sector and industry

Top strategic M&A buyers and acquirers in Dendreon's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Dendreon?

Top strategic M&A buyers groups and sectors for Dendreon include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Dendreon's sector and industry vertical

Which are the top PE firms investing in Dendreon's sector and industry vertical?

Top PE firms investing in Dendreon's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Dendreon's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Dendreon's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Dendreon's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Dendreon include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Dendreon's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Dendreon?

The key public trading comparables and valuation benchmarks for Dendreon include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Dendreon for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Dendreon with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Dendreon's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Dendreon with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Dendreon's' sector and industry vertical?

Access recent funding rounds and capital raises in Dendreon's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Dendreon